Results 221 to 230 of about 186,761 (273)

Near-complete pathologic resolution of untreated papillary thyroid cancer after pembrolizumab-induced thyroiditis. [PDF]

JCEM Case Rep
Locke M, Sternbach S, Seetharamu N, Taneja C.   +3 more
europepmc   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

Cost-effectiveness of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. [PDF]

Hum Vaccin Immunother
Yu K, Xu Q.
europepmc   +1 more source

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm

Internal Medicine Journal, EarlyView.
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie, J. E. Salem, A. Nagrial, A. Menzies, L. Thomas, S. Ramanathan, L. J. Berglund, S. C. Sasson, A. C. Grey, R. Habib, M. Wong, M. S. Carlino, B. Jeffrey, J. Mo, M. W. Lin   +14 more
wiley   +1 more source

INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. [PDF]

Clin Cancer Res
Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, Penkov K, Schenker M, Spigel DR, Daste A, Hong MH, Guo Y, Chisamore MJ, Washburn ML, Phillips-Jones A, Russell J, Roy-Ghanta S, Ellis C, Ballas M, Le Tourneau C.   +23 more
europepmc   +1 more source

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors

Cancer Science, EarlyView.
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama   +2 more
wiley   +1 more source

National survey of real‐world treatment patterns for early‐ and intermediate‐stage hepatocellular carcinoma reveals wide variation across Australian states

Internal Medicine Journal, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is a heterogeneous and multi‐disease state that is complex to manage and requires a multidisciplinary approach to optimise patient care. Best practice recommendations were proposed in the Australian HCC consensus statement published in 2020.
Stuart K. Roberts, Ammar Majeed, Kiran Rasaratnam, John K. Olynyk, Nicholas Shackel, Marnie Wood, Alan Wigg, Simone I. Strasser   +7 more
wiley   +1 more source

Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study. [PDF]

J Clin Med
Mildanoglu MM, Yucel MH, Engin Delipoyraz E, Sunger E, Ozcelik H, Fidan S, Terzioglu C, Muglu H, Hamdard J, Cakan Demirel B, Kutlu Y, Acikgoz O, Seker M, Bilici A.   +13 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source